

# Gilles Peytavin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4483052/publications.pdf>

Version: 2024-02-01

57  
papers

1,479  
citations

471509

17  
h-index

330143

37  
g-index

58  
all docs

58  
docs citations

58  
times ranked

2025  
citing authors

#	ARTICLE	IF	CITATIONS
1	Discordance Between Cerebral Spinal Fluid and Plasma HIV Replication in Patients with Neurological Symptoms Who Are Receiving Suppressive Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2010, 50, 773-778.	5.8	377
2	Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 209-221.	9.1	233
3	Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2016, 65, 40-47.	3.7	161
4	Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. <i>Aids</i> , 2004, 18, 1958-1961.	2.2	93
5	Prediction of human fetal pharmacokinetics using <i>ex vivo</i> human placenta perfusion studies and physiologically based models. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 646-657.	2.4	64
6	Placental transfer of lopinavir/ritonavir in the <i>ex vivo</i> human cotyledon perfusion model. <i>American Journal of Obstetrics and Gynecology</i> , 2006, 195, 296-301.	1.3	47
7	Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection. <i>Antiviral Research</i> , 2020, 181, 104866.	4.1	40
8	Contribution and limit of the model of perfused cotyledon to the study of placental transfer of drugs. Example of a protease inhibitor of HIV: Nelfinavir. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2009, 147, 157-160.	1.1	31
9	Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1648-1652.	3.0	29
10	Chronic Hepatitis E in a Heart Transplant Patient: Sofosbuvir and Ribavirin Regimen Not Fully Effective. <i>Antiviral Therapy</i> , 2018, 23, 463-465.	1.0	27
11	Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2742-2751.	3.0	26
12	Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2376-2380.	3.0	25
13	Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1404-1412.	3.0	25
14	A New Mechanism of Resistance of Human Immunodeficiency Virus Type 2 to Integrase Inhibitors: A 5-Amino-Acid Insertion in the Integrase C-Terminal Domain. <i>Clinical Infectious Diseases</i> , 2019, 69, 657-667.	5.8	22
15	Removal of Remdesivir's Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	21
16	Switch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012-2014. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv018.	0.9	17
17	Placental transfer of the integrase strand inhibitors cabotegravir and bicitegravir in the <i>ex-vivo</i> human cotyledon perfusion model. <i>Aids</i> , 2020, 34, 2145-2149.	2.2	17
18	Efficacy and Safety of Ritonavir/Indinavir 100/400 Mg Twice Daily in Combination with Two Nucleoside Analogues in Antiretroviral Treatment-Naive HIV-Infected Individuals. <i>Antiviral Therapy</i> , 2003, 8, 603-609.	1.0	17

#	ARTICLE	IF	CITATIONS
19	Placental Transfer of Darunavir in an <i>Ex Vivo</i> Human Cotyledon Perfusion Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5617-5620.	3.2	16
20	Bidirectional Transfer of Raltegravir in an <i>Ex Vivo</i> Human Cotyledon Perfusion Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3112-3114.	3.2	13
21	Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2657-2660.	3.0	13
22	Placental transfer of Letemovir & Maribavir in the ex vivo human cotyledon perfusion model. New perspectives for in utero treatment of congenital cytomegalovirus infection. <i>PLoS ONE</i> , 2020, 15, e0232140.	2.5	13
23	Clinical Validation of Saquinavir/Ritonavir Genotypic Resistance Score in Protease-Inhibitor-Experienced Patients. <i>Antiviral Therapy</i> , 2007, 12, 247-252.	1.0	13
24	Placental Transfer of Rilpivirine in an <i>Ex Vivo</i> Human Cotyledon Perfusion Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2901-2903.	3.2	12
25	Bariatric surgery in HIV patients: experience of an Obesity Reference Center in France. <i>Surgery for Obesity and Related Diseases</i> , 2017, 13, 1990-1996.	1.2	11
26	Placental transfer of elvitegravir and cobicistat in an ex-vivo human cotyledon double perfusion model. <i>Aids</i> , 2018, 32, 321-325.	2.2	10
27	Improvement of HIV-associated neurocognitive disorders after antiretroviral therapy intensification: the Neuro+3 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 743-752.	3.0	10
28	Tenofovir plasma concentrations related to estimated glomerular filtration rate changes in first-line regimens in African HIV-infected patients: ANRS 12115 DAYANA substudy. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1517-1521.	3.0	9
29	Metabolic syndrome and endocrine status in HIV-infected transwomen. <i>Aids</i> , 2019, 33, 855-865.	2.2	9
30	Concentration-response model of rilpivirine in a cohort of HIV-1-infected naive and pre-treated patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1992-2002.	3.0	8
31	Pharmacokinetics and Safety of Darunavir/Ritonavir in HIV-Infected Pregnant Women. <i>AIDS Reviews</i> , 2017, 19, 16-23.	1.0	7
32	Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 473-481.	1.9	6
33	Usefulness of therapeutic drug monitoring of rilpivirine and its relationship with virologic response and resistance in a cohort of naive and pretreated HIV-infected patients. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2404-2413.	2.4	6
34	Placental transfer of doravirine, a recent HIV-1 NNRTI in the <i>ex vivo</i> human cotyledon perfusion model. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2364-2367.	3.0	6
35	A disseminated <i>Mycobacterium marinum</i> infection in a renal transplant HIV-infected patient successfully treated with a bedaquiline-containing antimycobacterial treatment: A case report. <i>International Journal of Infectious Diseases</i> , 2021, 107, 176-178.	3.3	6
36	Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS 163 ETRAL Study. <i>Pharmacotherapy</i> , 2019, 39, 514-520.	2.6	4

#	ARTICLE	IF	CITATIONS
37	Failure of hydroxychloroquine pre-exposure prophylaxis in COVID-19 infection? A case report. Journal of Antimicrobial Chemotherapy, 2020, 75, 2706-2707.	3.0	4
38	Plasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study: Figure 1. Journal of Antimicrobial Chemotherapy, 2015, 70, 2418-2420.	3.0	3
39	Real life use of raltegravir during pregnancy in France: The Coferal-IMEA048 cohort study. PLoS ONE, 2019, 14, e0216010.	2.5	3
40	Reply to Yan and Muller, "Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir's Nephrotoxicity". Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	3
41	HIV-1 RNA Kinetics in Blood Plasma and in Seminal Plasma of Men Starting a Dolutegravir-Based Triple-Combination Regimen at the Time of Primary HIV-1 Infection. Journal of Infectious Diseases, 2022, 225, 116-120.	4.0	3
42	Bictegravir pharmacokinetics in a late-presenting HIV-1-infected pregnant woman: a case report. Journal of Antimicrobial Chemotherapy, 2022, 77, 851-853.	3.0	3
43	Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study authors' response. Journal of Antimicrobial Chemotherapy, 2020, 75, 3699-3700.	3.0	2
44	Characterization of drug resistance and the defective HIV reservoir in virally suppressed vertically infected children in Mali. Journal of Antimicrobial Chemotherapy, 2020, 75, 1272-1279.	3.0	2
45	Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial authors' response. Journal of Antimicrobial Chemotherapy, 2021, 76, 277-279.	3.0	2
46	Reply to: "Therapeutic drug monitoring for sofosbuvir and daclatasvir in transplant recipients with chronic hepatitis C and advanced renal disease". Journal of Hepatology, 2016, 65, 1065-1066.	3.7	1
47	Intermittent two-drug antiretroviral therapies maintain long-term viral suppression in real life in highly experienced HIV-infected patients. Journal of Antimicrobial Chemotherapy, 2021, 76, 1893-1897.	3.0	1
48	Efficacy and tolerability of combined antiretroviral treatment with bictegravir/emtricitabine/tenofovir alafenamide initiated at the time of primary HIV infection. Journal of Antimicrobial Chemotherapy, 2021, 76, 2484-2485.	3.0	1
49	Higher Atazanavir Plasma Exposure in Rats is Associated with Gut Microbiota Changes Induced by Cotrimoxazole. Current Drug Metabolism, 2019, 20, 898-906.	1.2	1
50	In vitro analysis of the replicative capacity and phenotypic susceptibility to integrase inhibitors of HIV-2 mutants with integrase insertions. Journal of Antimicrobial Chemotherapy, 2021, , .	3.0	1
51	Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen. Journal of Antimicrobial Chemotherapy, 2021, 76, 477-481.	3.0	0
52	Title is missing!. , 2020, 15, e0232140.		0
53	Title is missing!. , 2020, 15, e0232140.		0
54	Title is missing!. , 2020, 15, e0232140.		0

#	ARTICLE	IF	CITATIONS
55	Title is missing!. , 2020, 15, e0232140.		0
56	Title is missing!. , 2020, 15, e0232140.		0
57	Title is missing!. , 2020, 15, e0232140.		0